Rebecca Byam, Chief Financial Officer at HCW Biologics Inc. (HCWB), bought 14,235 shares at $1.41 ($20K) on 2026-05-22, disclosed to the SEC on 2026-05-27.
HCW Biologics CFO Rebecca Byam purchased $20,000 of stock at $1.41 per share, marking the largest insider purchase in the company's history. This move comes as the stock has surged over 350% in the last 30 days, suggesting the executive is betting on continued momentum.
The stock has experienced extreme volatility, rallying 354.65% over the last 30 days to reach $1.95, though it remains down 75.62% over the past year and sits 77.7% below its 52-week high of $8.75.
Coming off a massive 354.65% 30-day rally, the stock is currently trading at a forward P/E of -4.87, indicating potential earnings expectations are still catching up to the price action.
The stock is highly volatile with a beta of 2.36, and while short interest is low at 1.4%, the extreme percentage gains in recent weeks suggest the price may be detached from fundamentals.
Something here stands out, but not much.
| Filing → |
| HCWB | BUY | 2023-09-13 | $21K | — | Filing → |
| HCWB | BUY | 2023-09-08 | $20K | — | Filing → |
| HCWB | BUY | 2023-09-07 | $10K | — | Filing → |